180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company is headquartered in Palo Alto, California. The company went IPO on 2017-06-07. This strategy is built for the community, by the community. Through its partnership with Electric Capital, ETHZilla's treasury strategy aims to pursue a differentiated yield generation program meant to outperform traditional ETH staking. The firm has also been evolving its business towards software-enabled gaming and entertainment. In addition to its ETH treasury strategy, the Company continues to maintain and accelerate the deployment and development of its gaming initiatives.
Follow-Up Questions
¿Quién es el CEO de ETHZilla Corp?
Mr. McAndrew Rudisill es el Chairman de ETHZilla Corp, se unió a la empresa desde 2025.
¿Qué tal es el rendimiento del precio de la acción ETHZ?
El precio actual de ETHZ es de $1.68, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de ETHZilla Corp?
ETHZilla Corp pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de ETHZilla Corp?
La capitalización bursátil actual de ETHZilla Corp es $269.1M
